Core Viewpoint - The approval of the active pharmaceutical ingredient (API) for Milnacipran Hydrochloride marks a significant milestone for the company in the specialty API sector, enhancing its product line and demonstrating compliance with national drug registration standards [2][4][6]. Group 1 - The National Medical Products Administration has granted approval for the marketing application of Milnacipran Hydrochloride API [2][6]. - Milnacipran Hydrochloride is an oral selective serotonin and norepinephrine reuptake inhibitor (SNRI) used for the treatment of major depressive disorder [4][9]. - The approval signifies the company's commitment to the specialty API field and supports the integration of its product supply chain, optimizing resource allocation and enhancing market competitiveness [4][9].